




Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

Endocan Corporation

500 Madison Street Suite #104
Nashville, TN 37208

910.515.2917
www.omnicanna.com
Robert.kane@omnicanna.com
SIC code - 3999

Quarterly Report
For the Period Ending: March 31, 2021
(the "Reporting Period")

As of December 31, 2020, the number of shares outstanding of our Common Stock was:
587,936,147

As of March 31, 2021, the number of shares outstanding of our Common Stock was:

587,936,147

As of December 31, 2020 the number of shares outstanding of our Common Stock was:

587,936,147

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: ☐ No: ☒

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐ No: ☒

Indicate by check mark whether a Change in Control¹ of the company has occurred over this reporting period:

Yes: ☐ No: ☒

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

Current since March 31, 2021 Thermic Science Corporation

ENDOCAN Corporation until March 31, 2021

X-Change Corporation until 11-2013

Diversified Technologies until 12-2006

Cassco Capital Corp until 06-2000

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

Nevada

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

On March 31, 2021, the Company received the State of Nevada confirmation documents to confirm the ENDOCAN name change to: Thermic Science International Corporation.

On March 31, 2021, the Company received the State of Nevada confirmation documents to confirm the following share structure changes and amendments:

A. Preferred Voting 67% non-convertible Authorized: 1,000,000

Issued: 1,000,000

B. **Increased**, Common Shares

¹ "Change in Control" shall mean any events resulting in:

(i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;

(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;

(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

Authorized: 1,500,000,000 (**Increased, from 750mm**)

Issued: 650,000,000

C. **New**, Common Class A Authorized: 5,000,000,000

Issued: 0

D. **New**, Common Class B Authorized: 100,000,000

Issued: 0

E. **New**, Common Class C Authorized: 100,000,000

Issued: 0

2. On October 1, 2020, the Company acquired all of the issued and outstanding shares of Thermic Coating Systems, Ltd, of the United Kingdom. The transaction has not been completed and is anticipated to close shortly.
3. On December 17, 2020, the Company acquired Cannabis Science inc., in an all-share transaction. The transaction has not been completed and is anticipated to close shortly.
4. On March 8, 2021, the Company acquired all of the assets of Litcoat Electroluminescent Paint in an all share transaction. The transaction has not been completed and is anticipated to close shortly.

The address(es) of the issuer's principal executive office:

500 Madison Street, Suite 104, Nashville, TN 37208

The address(es) of the issuer's principal place of business:

Check box if principal executive office and principal place of business are the same address: ☒

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: ☐ No: ☒

If this issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below:

No

2) Security Information

Trading symbol:	<u>ENDO</u>
Exact title and class of securities outstanding:	<u>Common</u>
CUSIP:	<u>000054424</u>
Par or stated value:	<u>\$0.001</u>

Total shares authorized:	<u>750,000,000</u>	as of date: <u>March 31, 2021</u>
Total shares outstanding:	<u>587,936,147</u>	as of date: <u>March 31, 2021</u>
Number of shares in the Public Float ² :	<u>141,730,312</u>	as of date: <u>March 31, 2021</u>
Total number of shareholders of record:	<u>78</u>	as of date: <u>March 31, 2021</u>

All additional class(es) of publicly traded securities (if any):

Trading symbol: _____
 Exact title and class of securities outstanding: _____
 CUSIP: _____
 Par or stated value: _____
 Total shares authorized: _____ as of date: _____
 Total shares outstanding: _____ as of date: _____

Transfer Agent

Name: Signature Stock Transfer, Inc.
 Phone: 972.612.4120
 Email: info@signaturestocktransfer.com
 Address: Office in the Park, 14673 Midway Road, Suite #220, Addison, Texas 75001

Is the Transfer Agent registered under the Exchange Act?³ Yes: ☒ No: ☐

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period**.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares

[

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods: ☒

Shares Outstanding as of Second Most Recent Fiscal Year End:		*Right-click the rows below and select "Insert" to add rows as needed.
<u>Opening</u>		
<u>Balance</u>		
Date <u>12/31/2020</u>	Common:	
<u>587,936,147</u>		
	Preferred:	
<u>1,000,000</u>		

² "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

³ To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
<u>12/4/2019</u>	<u>New Issuance</u>	<u>20,000,000</u>	<u>Common</u>	<u>\$.003</u>	<u>No</u>	<u>Splenpoyous Inc. Amy Kromer</u>	<u>Consulting</u>	<u>Restricted</u>	<u>144</u>
<u>12/4/2019</u>	<u>New Issuance</u>	<u>10,000,000</u>	<u>Common</u>	<u>\$.003</u>	<u>No</u>	<u>Morris Johnson</u>	<u>Consulting</u>	<u>Restricted</u>	<u>144</u>
<u>12/4/2019</u>	<u>New Issuance</u>	<u>5,000,000</u>	<u>Common</u>	<u>\$.003</u>	<u>No</u>	<u>Thomas Kane</u>	<u>Consulting</u>	<u>Restricted</u>	<u>144</u>
<u>12/4/2019</u>	<u>New Issuance</u>	<u>10,000</u>	<u>Common</u>	<u>\$.003</u>	<u>No</u>	<u>Greta Gaines</u>	<u>Consulting</u>	<u>Restricted</u>	<u>144</u>
<u>12/4/2019</u>	<u>Cancellation</u>	<u>10,000</u>	<u>Common</u>	<u>\$.003</u>	<u>No</u>	<u>Greta Gaines</u>	<u>Consulting</u>	<u>Restricted</u>	<u>144</u>
<u>12/4/2019</u>	<u>New Issuance</u>	<u>10,000,000</u>	<u>Common</u>	<u>\$.003</u>	<u>No</u>	<u>Greta Gaines</u>	<u>Consulting</u>	<u>Restricted</u>	<u>144</u>
<u>12/7/2019</u>	<u>New Issuance</u>	<u>300,000,000</u>	<u>Common</u>	<u>\$.001</u>	<u>Yes</u>	<u>Raymond Dabney</u>	<u>Licensing Acquisition</u>	<u>Restricted</u>	<u>144</u>
<u>12/8/2019</u>	<u>New Issuance</u>	<u>25,000,000</u>	<u>Common</u>	<u>\$.004</u>	<u>No</u>	<u>Morris Johnson</u>	<u>Consulting</u>	<u>Restricted</u>	<u>144</u>
<u>12/8/2019</u>	<u>New Issuance</u>	<u>30,000,000</u>	<u>Common</u>	<u>\$.004</u>	<u>No</u>	<u>Splenpoyous Inc. Amy Kromer</u>	<u>Consulting</u>	<u>Restricted</u>	<u>144</u>
<u>1/27/2020</u>	<u>Cancellation</u>	<u>50,000,000</u>	<u>Common</u>	<u>\$.001</u>	<u>Yes</u>	<u>Raymond Dabney</u>	<u>Consulting</u>	<u>Restricted</u>	<u>144</u>

<u>1/27/2020</u>	<u>New Issuance</u>	<u>25,000,000</u>	<u>Common</u>	<u>\$.003</u>	<u>No</u>	<u>SK Business Group Sanjevi Rao</u>	<u>Consulting</u>	<u>Restricted</u>	<u>144</u>
<u>1/27/2020</u>	<u>New Issuance</u>	<u>25,000,000</u>	<u>Common</u>	<u>\$.003</u>	<u>No</u>	<u>Samer Nasan</u>	<u>Consulting</u>	<u>Restricted</u>	<u>144</u>
<u>6/15/2020</u>	<u>New issuance</u>	<u>40,000,000</u>	<u>Common</u>	<u>\$.008</u>	<u>No</u>	<u>Greta Gaines</u>	<u>Consulting</u>	<u>Restricted</u>	<u>144</u>
<u>6/29/2020</u>	<u>New Issuance</u>	<u>10,000,000</u>	<u>Common</u>	<u>\$.007</u>	<u>No</u>	<u>Norberto Guiterrez</u>	<u>Cash</u>	<u>Restricted</u>	<u>144</u>
<u>6/29/2020</u>	<u>New Issuance</u>	<u>25,000,000</u>	<u>Common</u>	<u>\$.007</u>	<u>No</u>	<u>Wayne Howey</u>	<u>Consulting</u>	<u>Restricted</u>	<u>144</u>
<u>12/16/2020</u>	<u>Cancellation</u>	<u>250,000,000</u>	<u>Common</u>	<u>\$.001</u>	<u>Yes</u>	<u>Raymond Dabney</u>	<u>Licensing</u>	<u>Restricted</u>	<u>144</u>
<u>12/16/2020</u>	<u>New Issuance</u>	<u>50,000,000</u>	<u>Common</u>	<u>\$.005</u>	<u>No</u>	<u>Anthony Spring</u>	<u>Consulting</u>	<u>Restricted</u>	<u>144</u>
<u>12/16/2020</u>	<u>New Issuance</u>	<u>10,000,000</u>	<u>Common</u>	<u>\$.005</u>	<u>No</u>	<u>Jean-Christophe Gerard</u>	<u>Consulting</u>	<u>Restricted</u>	<u>144</u>
<u>12/17/2020</u>	<u>New Issuance</u>	<u>35,000,000</u>	<u>Common</u>	<u>\$.001</u>	<u>Yes</u>	<u>Royalty Mgmt Services</u>	<u>Consulting</u>	<u>Restricted</u>	<u>144</u>
<u>12/17/2020</u>	<u>Cancellation</u>	<u>10,000,000</u>	<u>Common</u>	<u>\$.001</u>	<u>Yes</u>	<u>Royalty Mgmt Services</u>	<u>Consulting</u>	<u>Restricted</u>	<u>144</u>
<u>12/17/2020</u>	<u>New Issuance</u>	<u>10,000,000</u>	<u>Common</u>	<u>\$.006</u>	<u>No</u>	<u>Richard Dabney</u>	<u>Consulting</u>	<u>Restricted</u>	<u>144</u>
Shares Outstanding on Date of This Report:									
<u>Ending</u>									
<u>Balance Ending Balance:</u>									
<u>Date 12-31-2020</u>									
<u>Common: 558,872,294</u>									
<u>Preferred:</u>									
<u>1,000,000</u>									

Example: A company with a fiscal year end of December 31st, in addressing this item for its quarter ended September 30, 2020, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2018 through September 30, 2020 pursuant to the tabular format above.

Use the space below to provide any additional details, including footnotes to the table above:

B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe all outstanding promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities.

Check this box if there are no outstanding promissory, convertible notes or debt arrangements: ☐

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g. Loan, Services, etc.)
<u>10/8/2020</u>	<u>\$0</u>	<u>\$15,000</u>	<u>\$0</u>	<u>4/8/2021</u>	<u>Converts at \$.001/sh</u>	<u>Greta Gaines</u>	<u>Loan</u>
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____

Use the space below to provide any additional details, including footnotes to the table above:

4) Financial Statements

A. The following financial statements were prepared in accordance with:

- ☒ U.S. GAAP
☐ IFRS

B. The financial statements for this reporting period were prepared by (name of individual)⁴:

Name: Arun
Title: Accountant
Relationship to Issuer: Consultant

Provide the financial statements described below for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

⁴ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.

- C. Balance sheet;
- D. Statement of income;
- E. Statement of cash flows;
- F. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- G. Financial notes; and
- H. Audit letter, if audited

You may either (i) attach/append the financial statements to this disclosure statement or (ii) file the financial statements through OTCIQ as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial statements in a separate report as described above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to OTCIQ in the field below. Financial Statements must be compiled in one document.

Financial statement information is considered current until the due date for the subsequent report (as set forth in the qualifications section above). To remain qualified for Current Information, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of each fiscal quarter-end date.

5) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

- A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

Endocan Corporation also known as Thermic Science International Corporation (OTC: ENDO) has recently acquired Cannabis Science Inc., (CSi-EDP), Thermic Coating Systems Ltd. (UK), and now, Litcoat Electroluminescent Paint Systems. The Company has voted to change its name to Thermic Science International. A conglomerate SPAC Group designed to bring affordable and free education, traditional and entrepreneurial job creation, and cannabinoid drug development internationally.

We are currently developing new natural hemp-based products based on innovative formulations to utilize the unique and potent benefits of the hemp plant. With the aid of scientific research, Endocan also known as Thermic Science International Corporation is translating such knowledge into development of effective hemp formulation-based health and wellness solutions as well as cosmeceutical, nutraceutical, and food brands throughout the world. The Company's health and wellness, nutritional, and cosmetics lines will address personal needs and will evolve with the introduction of new formulations and products, advancing the Company within the expanding multibillion-dollar global market.

We currently have a licensing agreement for Live Negotiator. Live Negotiator provides powerful online tools to buyers and sellers of industrial hemp products, services, supplies. Live Negotiator allows users to find and track inventory, purchase, and negotiate live worldwide. The system provides private, one on one, and one to many negotiations while dynamically loading and matching inventory changes while instantly updating new inventory and opportunities in real time. The Live

Negotiator software provides advanced and key tools in the saturated industrial hemp market. This version of the Live Negotiator technology includes industrial, medical, wholesale, and retail hemp products worldwide.

B. Please list any subsidiaries, parents, or affiliated companies.

On October 1, 2020, the Company acquired all of the issued and outstanding shares of Thermic Coating Systems, Ltd, of the United Kingdom. The transaction has not been completed and is anticipated to close shortly.

On December 17, 2020, the Company acquired Cannabis Science inc., in an all-share transaction. The transaction has not been completed and is anticipated to close shortly.

On March 8, 2021, the Company acquired all of the assets of Litcoat Electroluminescent Paint in an all share transaction. The transaction has not been completed and is anticipated to close shortly.

B. Describe the issuers' principal products or services.

The Thermic brand of products include Thermic Heating Paint and Portable Thermic Heating Units

With this product you can paint any wall, ceiling, or floor into an infrared heating panel. Large sized Infrared heaters on low temperature on walls and ceilings we believe are the future.

The Hempery brand of products include hemp based personal care items such as body oil, soap, body wash, and lip balm.

The HempTasty brand of hemp-based foods include spices and sauces.

6) Issuer's Facilities

500 Madison St, Suite 104, Nashville, TN 37208. Renews August 16, 2021 Other facilities are owned by partners and contractors for research and development, sales and distribution. In the future we plan on having our own facilities for these operational requirements.

7) Company Insiders (Officers, Directors, and Control Persons)

Using the tabular format below, please provide information, as of the period end date of this report, regarding any person or entity owning 5% or more of any class of the issuer's securities, as well as any officer, and any director of the company, or any person that performs a similar function, regardless of the number of shares they own. **If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.**

Name of Officer/Director or Control Person	Affiliation with Company (e.g. Officer Title /Director/Owner	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note

	of more than 5%)					
<u>Raymond Dabney</u>	Owner CEO	<u>Vancouver, BC</u>	<u>1,000,000</u>	<u>Preferred</u>	<u>100%</u>	_____
<u>Raymond Dabney</u>	Owner CEO	<u>Vancouver, BC</u>	<u>0</u>	<u>Common</u>	<u>0</u>	
<u>Robert Kane</u>	<u>CFO</u>	<u>Leland, NC</u>	<u>0</u>	<u>Common</u>	0%	_____
<u>Greta Gaines</u>	<u>Owner of more than 5%</u>	<u>Nashville, TN</u>	<u>50,000,000</u>	<u>Common</u>	<u>6.7%</u>	_____
<u>Anthony Spring</u>	<u>Owner of more than 5%</u>	<u>Netherlands</u>	<u>50,000,000</u>	Common	6.7%	_____
<u>Splenpoyous</u> <u>Amy Kromer</u>	<u>Owner of more than 5%</u>	<u>Effort, PA</u>	<u>50,000,000</u>	Common	<u>6.7%</u>	_____

8) Legal/Disciplinary History

A. Please identify whether any of the persons or entities listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

No

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

No

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

No

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

No

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

9) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

Securities Counsel

Name: Jerry Chesler
Firm: _____
Address 1: PO Box 2987
Address 2: Carefree AZ 85377
Phone: 480.235.3368
Email: _____

Accountant or Auditor

Name: Robert Kane
Firm: _____
Address 1: 500 Madison St. suite 104
Address 2: Nashville, TN 37208
Phone: _____
Email: Robert.kane@omnicanna.com

Investor Relations

Name: _____
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s) or consultant(s) or provided assistance or services to the issuer during the reporting period.

Name: _____
Firm: _____
Nature of Services: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Raymond Dabney certify that:

1. I have reviewed this annual statement of Endocan;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

August 9, 2021 [Date]

/s/ (Raymond Dabney) [CEO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

Principal Financial Officer:

I, Robert Kane certify that:

1. I have reviewed this annual disclosure statement of Endocan Corporation;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

August 9, 2021 [Date]

/s/(Robert Kane) [CFO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")